The
statins are a class of
3-hydroxy-3-methylglutaryl-coenzyme A-
reductase inhibitors that are recognized to have pleiotropic properties. We previously reported the attenuation of LPS-induced murine
acute lung injury (ALI) by
simvastatin in vivo and identified relevant effects of
simvastatin on endothelial cell (EC) signaling, activation, and barrier function in vitro. In particular,
simvastatin induces the upregulation of integrin-β4, which in turn inhibits EC inflammatory responses via attenuation of MAPK signaling. The role of integrin-β4 in murine ALI protection by
simvastatin, however, is unknown. We initially confirmed a time- and dose-dependent effect of
simvastatin on increased integrin-β4
mRNA expression in human lung EC with peak
protein expression evident at 16 h. Subsequently, reciprocal immunoprecipitation demonstrated an attenuation of LPS-induced integrin-β4
tyrosine phosphorylation by
simvastatin (5 μM, 16 h). Increased expression of EC inflammatory
cytokines [IL-6,
IL-8,
monocyte chemoattractant protein (MCP)-1, regulated on activation normal T cell expressed and secreted (
RANTES)] by LPS (500 ng/ml, 4 h) was also significantly attenuated by
simvastatin pretreatment (5 μM, 16 h), but this effect was reversed by cotreatment with an integrin-β4-blocking antibody. Finally, although
simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts,
protein, inflammatory
cytokines (IL-6, IL-1β, MCP-1, RANTES), decreased
Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-β4-blocking antibody (IV, 1 mg/kg, 2 h before LPS). These findings support integrin-β4 as an important mediator of ALI protection by
simvastatin and implicate signaling by integrin-β4 as a novel therapeutic target in patients with ALI.